Has Kamran Mahmood, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,248 in general payments to Kamran Mahmood, MD across 31 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kamran Mahmood, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kamran Mahmood, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kamran Mahmood, MD

Infectious Disease · London, KYNPI 1346251345

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $794 of the $1,248 with a category attached, or 63.6%. Intuitive Surgical accounts for 63.6% of it on its own, with 7 other manufacturers making up the rest. 2023 is the largest year on record at $794, 2.1 times the $380 reported in 2019.

$1,248in general payments, 2019–2025

Across 31 payments — averaging $40.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intuitive Surgical$794
Astellas Pharma US Inc$192
Johnson & Johnson$82
AbbVie$57
Insmed, Inc.$34
Gilead$33
plus $55 from 2 others

What the payments were for

Travel & lodging$79464%
Food & beverage$34728%
Education$1079%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intuitive Surgical	5	$794
Astellas Pharma US Inc	8	$192
Johnson & Johnson	6	$82
AbbVie	4	$57
Insmed, Inc.	2	$34
Gilead	2	$33
Tetraphase Pharmaceuticals, Inc.	2	$30
Pfizer	2	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Da Vinci Surgical System$775

How this compares

$1,248 in reported general payments places this provider in the 55th percentile of 100 infectious disease providers in Kentucky.

See all infectious disease providers in Kentucky →

Medicare billing

Part B allowed, 2024

$135,737

Medicare patients

384

Services billed

1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	93	$381,634
PrezcobixDarunavir/Cobicistat	12	$26,674
DescovyEmtricitabine/Tenofov Alafenam	13	$22,923
PifeltroDoravirine	16	$22,825
IsentressRaltegravir Potassium	13	$20,786
Vancomycin Hcl	34	$9,430
Rifampin	119	$5,879
Ethambutol Hcl	93	$5,032
Daptomycin	17	$4,069
Fosfomycin Tromethamine	28	$3,046
Cefepime Hcl	14	$2,749
Azithromycin	98	$2,213
Cephalexin	104	$1,608
CeftriaxoneCeftriaxone Sodium	32	$1,297
Cefazolin Sodium	19	$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GileadBiktarvy, Descovy	$33	$404,558106 claims
Johnson & JohnsonPrezcobix	$82	$26,67412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 100 infectious disease providers in Kentucky.

Other infectious disease in London

Arif KhanLondon$605
Fadi Al AkhrassPikeville$311K
Julio RamirezLouisville$256K
Martin GnoniLouisville$194K
Paul SchulzLouisville$189K
David DoughertyLexington$145K
Tariq MehmoodLouisville$75K
Charles RoseLexington$68K
Wajdi KfouryCorbin$59K
Marty AllenLexington$40K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →